PF-06671008 Dose Escalation Study in Advanced Solid Tumors
Public ClinicalTrials.gov record NCT02659631. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WITH ADVANCED SOLID TUMORS
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06671008 in patients with advanced solid tumors with the potential to have P-cadherin expression. The study will then expand to look at the selected dose in patients with P-cadherin expressing TNBC, CRC or NSCLC.
Study identification
- NCT ID
- NCT02659631
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 28 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 28, 2016 (Actual)
- Primary completion
- Mar 29, 2019 (Actual)
- Completion
- Mar 29, 2019 (Actual)
- Last update posted
- May 6, 2020
2016 – 2019
United States locations
- U.S. sites
- 9
- U.S. states
- 4
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Memorial Sloan Kettering Cancer Center - Westchester | Harrison | New York | 10604 | — |
| Memorial Sloan Kettering Cancer Center- Clinical Trials Office | New York | New York | 10017 | — |
| Memorial Sloan Kettering Cancer Center Rockefeller Outpatient Pavillion | New York | New York | 10022 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| The University of Texas - M.D. Anderson Cancer Center | Houston | Texas | 77030 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Huntsman Cancer Hospital | Salt Lake City | Utah | 84112 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02659631, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 6, 2020 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02659631 live on ClinicalTrials.gov.